A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

Last updated: May 1, 2024
Sponsor: N/A
Overall Status: Active - Recruiting

Phase

N/A

Condition

Diabetes Prevention

Diabetes Mellitus, Type 2

Treatment

N/A

Clinical Study ID

TX322066
  • Ages 18-90
  • All Genders

Study Summary

The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. CagriSema will be compared to the two medicines semaglutide and cagrilintide, when they are taken alone. CagriSema will also be compared to a "dummy" medicine without any active ingredient. The study will be done in participants who have type 2 diabetes. Participants will take the study medicine together with the current diabetes medicine (metformin with or without an SGLT2 inhibitor).

Eligibility Criteria

Inclusion

Inclusion Criteria

  • Be 18+ years of age.
  • Diagnosed with Type 2 Diabetes for 6 months or longer.
  • Have a body mass index (BMI) ≥ 25 kg/m2.
  • Have an HbA1c 7% - 10.5%
  • Taking Metformin and on stable treatment for T2D for at least 90 days prior to screening.

Study Design

Study Start date:
Estimated Completion Date:

Study Description

Additional study details available by filling out the information below.

Connect with a study center

  • Headlands Research- AMCR Institute

    Escondido, California 92025
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.